Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer

Aude-Helene Capietto
Washington University School of Medicine in St. Louis

Seokho Kim
Washington University School of Medicine in St. Louis

Dominic E. Sanford
Washington University School of Medicine in St. Louis

David C. Linehan
Washington University School of Medicine in St. Louis

Masaki Hikida
RIKEN Research Center for Allergy and Immunology

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/1870

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Down-regulation of PLCγ2–β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer

Aude-Hélène Capietto,1 Seokho Kim,1 Dominic E. Sanford,2 David C. Linehan,2 Masaki Hikida,4 Tomohiro Kumosaki,4 Deborah V. Novack,3 and Roberta Faccio1

Myeloid-derived suppressor cells (MDSCs) favor tumor promotion, mainly by suppressing antitumor T cell responses in many cancers. Although the mechanism of T cell inhibition is established, the pathways leading to MDSC accumulation in bone marrow and secondary lymphoid organs of tumor-bearing hosts remain unclear. We demonstrate that down-regulation of PLCγ2 signaling in MDSCs is responsible for their aberrant expansion during tumor progression. PLCγ2–/− MDSCs show stronger immune-suppressive activity against CD8+ T cells than WT MDSCs and potently promote tumor growth when adoptively transferred into WT mice. Mechanistically, PLCγ2–/− MDSCs display reduced β-catenin levels, and restoration of β-catenin expression decreases their expansion and tumor growth. Consistent with a negative role for β-catenin in MDSCs, its deletion in the myeloid population leads to MDSC accumulation and supports tumor progression, whereas expression of β-catenin constitutively active reduces MDSC numbers and protects from tumor growth. Further emphasizing the clinical relevance of these findings, MDSCs isolated from pancreatic cancer patients show reduced p-PLCγ2 and β-catenin levels compared with healthy controls, similar to tumor-bearing mice. Thus, for the first time, we demonstrate that down-regulation of PLCγ2–β-catenin pathway occurs in mice and humans and leads to MDSC-mediated tumor expansion, raising concerns about the efficacy of systemic β-catenin blockade as anti-cancer therapy.

Accumulating evidence indicates that myeloid-derived suppressor cells (MDSCs) are critically involved in tumor progression. Despite the ambiguity surrounding their origin, MDSCs are recognized for their ability to suppress antitumor immune responses. MDSCs exert their pro-neoplastic effects through the release of small soluble oxidizers, impairment of T cell antigen recognition, and depletion of essential amino acids from the local extracellular environment, all ultimately leading to T cell suppression (Mazzoni et al., 2002; Kusmartsev and Gabrilovich, 2003; Liu et al., 2003; Kusmartsev et al., 2004; Kusmartsev et al., 2005; Zea et al., 2005; Gallina et al., 2006). Additionally, MDSCs shift immune regulation to a state favoring both tumor escape and proliferation through overproduction of cytokines and angiogenic factors (Kusmartsev and Gabrilovich, 2006). Thus, it is not surprising that presence of MDSCs in the blood and tumor biopsies of cancer patients is associated with poor prognosis (Almand et al., 2001; Lechner et al., 2011; Solito et al., 2011; Porembka et al., 2012).

MDSCs comprise a heterogeneous population of immature myeloid cells (Bronte et al., 2000; Gabrilovich et al., 2001; Liu et al., 2003; Kusmartsev et al., 2004; Kusmartsev et al., 2005; Zea et al., 2005; Gallina et al., 2006), identified by the co-expression of Gr-1 and αm

S. Kim’s present address is Korea Research Institute of Bioscience and Biotechnology, 125 Gwahann, Yuseong-gu, Daejeon 305-806, Korea.
MDSC expansion in the bone marrow of tumor-bearing mice and enhances MDSC immunosuppressive activities via modulation of β-catenin levels. Together these results highlight a novel molecular pathway regulating the expansion of MDSCs and their crucial role in tumor progression.

RESULTS
MDSCs are responsible for increased tumor growth in PLCy2−/− mice
To understand the mechanism responsible for the impaired antitumor T cell response observed in PLCy2−/− mice, we measured the percentage of MDSCs after s.c. inoculation of B16 melanoma and Lewis lung carcinoma (LLC) cell lines. Consistent with a significant increase in s.c. tumor growth in PLCy2−/− mice, we also found a higher percentage of Gr-1+CD11b+ MDSCs in the bone marrow, spleen, and tumor site 14 d after inoculation of both tumor cell lines (Fig. 1, A and B). The increase in percentage of MDSCs observed in the null mice was not detected at baseline, reflecting a rather specific response to the tumor itself (not shown). Between the two cell lines, LLC induced stronger MDSC accumulation than B16 cells in both PLCy2−/− and WT mice, and thus this cell line was used for all subsequent experiments. Next, to determine whether the expanded MDSC population observed in the null mice was a consequence of greater tumor growth, we injected WT and PLCy2−/− mice with 106 LLC and sacrificed the animals 7 d after tumor challenge when no detectable differences in tumor weight were yet observed (Fig. 1 C). PLCy2−/− mice already displayed greater MDSC accumulation in bone marrow and spleen, whereas only a small percentage of MDSCs was detected in the tumor at this time in both genotypes (Fig. 1 C).

To determine whether increased numbers of MDSCs are responsible for enhanced tumor growth in PLCy2−/− mice, we adoptively transferred 3 × 106 MDSCs isolated from LLC tumor-bearing PLCy2−/− or WT mice into WT animals. MDSCs were i.v. injected into the recipient mice 3 and 6 d after s.c. LLC inoculation. Tumor growth was monitored for 2 wk, and the percentage of MDSCs in the spleen was measured at time of sacrifice. We found that adoptive transfer of PLCy2−/− MDSCs into WT recipients significantly enhanced tumor growth compared with animals receiving WT MDSCs, and it also further increased MDSC accumulation in the spleen (Fig. 2 A). To address whether the expansion of MDSCs caused by administration of PLCy2-deficient MDSCs was caused by proliferation of the null cells or by increased expansion of endogenous MDSCs, we adoptively transferred CD45.2+ PLCy2−/− or WT MDSCs into tumor-bearing CD45.1+ WT recipients. Mice injected with saline were used as controls. Tumor growth was monitored for 14 d and the percentage of endogenous CD45.1+ MDSCs and total Gr-1+CD11b+ MDSCs (CD45.1+ and CD45.2+) in the spleen was analyzed at time of sacrifice. As in Fig. 2 A, animals receiving PLCy2−/− MDSCs showed increased tumor growth compared with animals receiving WT MDSCs, accompanied by greater MDSC expansion (Fig. 2 B). Interestingly, the...
accumulation of MDSCs after adoptive transfer of either WT or PLCγ2−/− cells was due to expansion of endogenous CD45.1+ MDSCs, as their percentage was similar to that of total MDSCs (Fig. 2B and not depicted). This finding indicates that the transfer of exogenous PLCγ2-deficient MDSCs into WT recipient animals causes the expansion of endogenous MDSCs, which might be the result of enhanced tumor growth.

Next, to use a second approach to show that PLCγ2 deficiency in the myeloid population, including MDSCs, is responsible for the observed tumor phenotype, we turned to PLCγ2 conditional KO mice (PLCγ2cKO), in which deletion of PLCγ2 is under control of LysM-Cre. Reduced PLCγ2 expression in MDSCs was confirmed by Western blot, and similarly to the global PLCγ2−/− mice, PLCγ2cKO animals also displayed increased tumor growth and MDSC accumulation compared with LysM-Cre controls (not shown).

As MDSCs have also a recognized role in tolerance, we next analyzed whether PLCγ2−/− mice, which are on a C57BL/6 background, could allow growth of the allogeneic 4T1 breast cancer cell line derived from BALB/c mice. 5 × 10^6 4T1 tumor cells were inoculated s.c. in WT and PLCγ2−/− mice and tumor growth followed for 2 wk. As expected by the different background of the recipient C57BL/6 mice and the 4T1 tumor cell line isolated from BALB/c mice, the tumor engraftment was rejected in WT mice (Fig. 3). However, 4T1 tumor cells grew in PLCγ2−/− mice with a concomitant accumulation of MDSCs in the bone marrow and a 2.5 fold-increase in the percentage of MDSCs in the spleen (Fig. 3). All together these results indicate that PLCγ2 is a negative regulator of MDSC expansion and function in tumor-bearing hosts.

**PLCγ2 deficiency favors MDSC accumulation over myeloid cell differentiation in vitro**

To better understand the role of PLCγ2 in MDSC accumulation, we isolated MDSCs from the spleen of tumor-bearing mice and analyzed the balance between anti- (Bcl-2, Bcl-xl) and proapoptotic (Bax) signals by quantitative RT-PCR. PLCγ2−/− MDSCs showed similar relative mRNA expression levels of Bcl-2, Bcl-xl, and Bax to WT MDSCs (not depicted). Next, we wondered whether PLCγ2 deficiency would affect the cell fate differentiation from myeloid progenitor cells in the bone marrow. We isolated lineage negative hematopoietic progenitor cells from PLCγ2−/− or WT bone marrow and cultured them in the presence of GM-CSF, IL-4, and proapoptotic (Bax) signals by quantitative RT-PCR. PLCγ2−/− MDSCs showed similar relative mRNA expression levels of Bcl-2, Bcl-xl, and Bax to WT MDSCs (not depicted).
PLCγ2 deficiency expands PMN- and MO-MDSC subsets and potentiates their immunosuppressive functions

To gain more insights into the role of PLCγ2 in MDSC-induced tumor progression, we performed phenotypic and functional analyses comparing WT and PLCγ2−/− MDSCs during tumor progression. We measured the relative proportion of PMN-MDSCs (CD11b+Ly6G+Ly6C−) and MO-MDSCs (CD11b+Ly6G−Ly6C+high) by FACS in PLCγ2−/− and WT mice. We first confirmed that the percentage of both PMN- and MO-MDSC subsets in bone marrow and spleen was similar at baseline in the two genetic backgrounds (Fig. 4 A). PMN-MDSCs represented the dominant subpopulation before and after the tumor challenge in both WT and KO (Fig. 4, A and B). However, both MDSC subfractions were significantly increased in bone marrow and spleen of PLCγ2−/− mice compared with WT mice in response to LLC-tumor inoculation (Fig. 4 B). Thus, PLCγ2 does not seem to exert differential effects on PMN- and MO-MDSC subsets.

Next, to determine whether PLCγ2−/− MDSCs exhibited stronger immunosuppressive functions compared with WT, in addition to being more numerous, we examined the inhibitory effects of PMN- and MO-MDSCs on T cell proliferation in vitro. As MDSCs were shown to suppress both antigen-driven and mitogen-driven T cell proliferation, we examined the immune-suppressive activity of MDSCs under both conditions. Splenocytes from OT-1 transgenic mice were labeled with CFSE and incubated with MHC class I–restricted SIINFEKL (OT-1) peptide (10 nM) to induce CD8+ T cell antigen–specific proliferation or with anti-CD3 antibody (10 µg/ml) for mitogen-driven CD8+ T cell stimulation. The immune-suppressive effects of MDSCs were determined by culturing WT and PLCγ2−/− PMN- or MO-MDSCs with three different ratios of splenocytes (1:10; 1:5; 1:1). Proliferation of targeted CD8+ T cells was measured in terms of CFSE dilution by flow cytometric analysis 72 h later. We found that both PLCγ2−/− PMN- and MO-MDSCs had greater immune-suppressive effects on CD8+ T cell proliferation than WT MDSCs in both antigen- and mitogen-driven T cell stimulatory conditions (Fig. 5, A and B). It is established that PMN-MDSCs inhibit CD8+ T cell proliferation in vitro. As MDSCs were shown to suppress both antigen-driven and mitogen-driven T cell proliferation, we measured the relative proportion of PMN-MDSCs (CD11b+Ly6G+Ly6C−) and MO-MDSCs (CD11b+Ly6G−Ly6C+high) by FACS in PLCγ2−/− and WT mice. We first confirmed that the percentage of both PMN- and MO-MDSC subsets in bone marrow and spleen was similar at baseline in the two genetic backgrounds (Fig. 4 A). PMN-MDSCs represented the dominant subpopulation before and after the tumor challenge in both WT and KO (Fig. 4, A and B). However, both MDSC subfractions were significantly increased in bone marrow and spleen of PLCγ2−/− mice compared with WT mice in response to LLC-tumor inoculation (Fig. 4 B). Thus, PLCγ2 does not seem to exert differential effects on PMN- and MO-MDSC subsets.

Next, to determine whether PLCγ2−/− MDSCs exhibited stronger immunosuppressive functions compared with WT, in addition to being more numerous, we examined the inhibitory effects of PMN- and MO-MDSCs on T cell proliferation in vitro. As MDSCs were shown to suppress both antigen-driven and mitogen-driven T cell proliferation, we examined the immune-suppressive activity of MDSCs under both conditions. Splenocytes from OT-1 transgenic mice were labeled with CFSE and incubated with MHC class I–restricted SIINFEKL (OT-1) peptide (10 nM) to induce CD8+ T cell antigen–specific proliferation or with anti-CD3 antibody (10 µg/ml) for mitogen-driven CD8+ T cell stimulation. The immune-suppressive effects of MDSCs were determined by culturing WT and PLCγ2−/− PMN- or MO-MDSCs with three different ratios of splenocytes (1:10; 1:5; 1:1). Proliferation of targeted CD8+ T cells was measured in terms of CFSE dilution by flow cytometric analysis 72 h later. We found that both PLCγ2−/− PMN- and MO-MDSCs had greater immune-suppressive effects on CD8+ T cell proliferation than WT MDSCs in both antigen- and mitogen-driven T cell stimulatory conditions (Fig. 5, A and B). It is established that PMN-MDSCs inhibit CD8+ T cell proliferation mainly through ROS production and that MO-MDSCs induce T cell apoptosis mostly via NO release. To evaluate the mechanism by which PLCγ2 deficiency controls MDSC immune suppressive activity, we measured ROS and NO levels in PMN- and MO-MDSCs in response to PMA (300 nM) or LPS (1 µg/ml) for indicated time. As expected (Movahedi et al., 2008; Youn et al., 2008), WT PMN-MDSCs predominantly produced ROS, whereas WT MO-MDSCs mainly released nitrites (Fig. 5, C and D). In contrast, PMN-MDSCs

Figure 2. Adoptive transfer of PLCγ2−/− MDSCs enhances tumor growth in WT mice. (A) WT mice s.c. inoculated with LLC cells were adoptively transferred on days 3 and 6 with 3 × 106 WT or PLCγ2−/− MDSCs from LLC tumor–bearing mice. Tumor growth was followed for 14 d, and the percentage of endogenous PMN-MDSCs (CD11b+Ly6G+Ly6C−) and MO-MDSCs (CD11b+Ly6G−Ly6C+high) by FACS in PLCγ2−/− and WT mice. We first confirmed that the percentage of both PMN- and MO-MDSC subsets in bone marrow and spleen was similar at baseline in the two genetic backgrounds (Fig. 4 A). PMN-MDSCs represented the dominant subpopulation before and after the tumor challenge in both WT and KO (Fig. 4, A and B). However, both MDSC subfractions were significantly increased in bone marrow and spleen of PLCγ2−/− mice compared with WT mice in response to LLC-tumor inoculation (Fig. 4 B). Thus, PLCγ2 does not seem to exert differential effects on PMN- and MO-MDSC subsets.

Next, to determine whether PLCγ2−/− MDSCs exhibited stronger immunosuppressive functions compared with WT, in addition to being more numerous, we examined the inhibitory effects of PMN- and MO-MDSCs on T cell proliferation in vitro. As MDSCs were shown to suppress both antigen-driven and mitogen-driven T cell proliferation, we examined the immune-suppressive activity of MDSCs under both conditions. Splenocytes from OT-1 transgenic mice were labeled with CFSE and incubated with MHC class I–restricted SIINFEKL (OT-1) peptide (10 nM) to induce CD8+ T cell antigen–specific proliferation or with anti-CD3 antibody (10 µg/ml) for mitogen-driven CD8+ T cell stimulation. The immune-suppressive effects of MDSCs were determined by culturing WT and PLCγ2−/− PMN- or MO-MDSCs with three different ratios of splenocytes (1:10; 1:5; 1:1). Proliferation of targeted CD8+ T cells was measured in terms of CFSE dilution by flow cytometric analysis 72 h later. We found that both PLCγ2−/− PMN- and MO-MDSCs had greater immune-suppressive effects on CD8+ T cell proliferation than WT MDSCs in both antigen- and mitogen-driven T cell stimulatory conditions (Fig. 5, A and B). It is established that PMN-MDSCs inhibit CD8+ T cell proliferation mainly through ROS production and that MO-MDSCs induce T cell apoptosis mostly via NO release. To evaluate the mechanism by which PLCγ2 deficiency controls MDSC immune suppressive activity, we measured ROS and NO levels in PMN- and MO-MDSCs in response to PMA (300 nM) or LPS (1 µg/ml) for indicated time. As expected (Movahedi et al., 2008; Youn et al., 2008), WT PMN-MDSCs predominantly produced ROS, whereas WT MO-MDSCs mainly released nitrites (Fig. 5, C and D). In contrast, PMN-MDSCs

Figure 3. PLCγ2−/− mice permit 4T1 allogeneic tumor growth. 5 × 106 4T1 mammary tumor cells were s.c. injected in PLCγ2−/− or WT mice and tumor growth was evaluated for 14 d. Percentage of MDSCs in spleen was then analyzed by FACS using anti–Gr-1 and CD11b staining. Results represent mean ± SD (n = 3). One representative experiment of two is shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Reduced β-catenin levels are observed in PLCγ2−/− MDSCs

Dysregulated β-catenin signaling has been noted in many cancers. Furthermore, β-catenin pathway is also known to modulate the self-renewal and maintenance of hematopoietic stem cells and myeloid progenitor cells (Scheller et al., 2006). Because MDSCs are immature myeloid progenitor cells, we hypothesized that β-catenin could be an important player in their development. First, we confirmed deletion of PLCγ2 and reduced phosphorylation levels of the PLCγ2 effector PKC (p-PKC; Fig. 6 A). Next, we measured β-catenin and phosphorylated-GSK3β (p-GSK3β) levels in WT and PLCγ2−/− MDSCs isolated from tumor-bearing mice by Western blot. Surprisingly, we observed a striking decrease in β-catenin and p-GSK3β levels in PLCγ2−/− MDSCs compared with WT (Fig. 6 A). Because PKC has been previously shown to stabilize β-catenin protein levels in T cells (Lovatt and Bijlmakers, 2010), we wondered if reduced PKC activation in PLCγ2−/− MDSCs could be responsible for decreasing β-catenin levels. To address this question, we turned to the DAG-analogue phorbol 12,13-dibutyrate (PDBu), which can induce PKC activation similarly to endogenous DAG but even in the absence of PLCγ2 (Castagna et al., 1982). Whole PLCγ2−/− bone marrow cells were cultured in the presence of PDBu for 18 h, MDSCs were isolated and β-catenin protein levels were determined by Western blot. Results show increased β-catenin protein levels in PLCγ2-deficient MDSCs treated with PDBu compared with untreated cells (Fig. 6 B), indicating that PLCγ2 can regulate β-catenin levels via DAG-dependent PKC activation.

β-catenin deficiency in myeloid cells leads to greater tumor growth and MDSC accumulation

To further understand the importance of β-catenin down-regulation in MDSCs in vivo, we turned to the Cre-loxP recombination system to conditionally delete β-catenin in myeloid cells. β-catenin−floxed mice were bred with animals expressing the Cre recombinase under the control of Lyszyme M (LysM-Cre/β-cateninlox/lox; herein defined as β-cat. cKO), and deletion of β-catenin in MDSCs was confirmed by Western blot (not shown). We used animals expressing either the Cre recombinase (LysM-Cre/β-cateninlox/lox) or the floxed allele (β-cateninlox/lox) as a control (CTR). As no differences in tumor growth and MDSC expansion in the two control genotypes were observed, we used either one or the other as control group. LLC tumor cell line was inoculated s.c. into β-cat.cKO or control mice, and tumor growth was followed by caliper measurements for 14 d. The percentage of MDSCs in the bone marrow, spleen, and tumor site was analyzed by flow cytometry at time of sacrifice. Similarly to PLCγ2−/− mice, β-cat.cKO animals displayed greater tumor growth and over twofold increase in the percentage of MDSCs in spleen and tumor site compared with CTR (Fig. 6 C). A significant increase in the percentage of MDSCs in the bone marrow was also observed. To further determine the ability of β-catenin-deficient MDSCs to support tumor growth, we adoptively transferred MDSCs isolated from tumor-bearing β-cat.cKO or CTR mice into tumor-bearing WT mice. Mice receiving saline were used as additional controls. We found that mice transferred with β-cat.cKO MDSCs displayed enhanced tumor volume and twofold increase in splenic MDSCs compared with animals receiving CTR MDSCs or saline (Fig. 6 D).

β-catenin stabilization in myeloid cells protects from tumor growth by reducing MDSC accumulation and function

To further demonstrate that β-catenin is a critical modulator of MDSC expansion in response to tumor, we turned to a similar LysM-Cre-loxP genetic mouse model to express a constitutively active mutant of β-catenin (LysM-Cre/β-cateninfas/lox, herein defined as β-cat.CA; Harada et al., 1999) in myeloid cells, including MDSCs (not shown). LLC cells were inoculated s.c. into β-cat.CA and LysM-Cre CTR mice. Tumor growth was monitored every 2 d, and MDSC accumulation in bone marrow, spleen, and tumor site was evaluated 14 d after tumor challenge. In contrast to β-cat.cKO mice, expression of a stable form of β-catenin in MDSCs reduced tumor growth compared with
MDSCs were more potent immune suppressors than WT MDSCs at 1:1 ratio (Fig. 7 B). Collectively, these results indicate that modulation of β-catenin levels in MDSCs is critical for their accumulation and function and for modulation of tumor progression.

β-catenin stabilization in PLCγ2−/− MDSCs decreases their accumulation and immune suppressive activity

Next, to determine if PLCγ2 controls MDSC expansion in response to tumor via β-catenin, we bred LysM-Cre PLCγ2 conditional KO mice (PLCγ2cKO) with LysM-Cre/β-cateninLoxPLoxEx3/LoxEx3 mice (β-cat.CA) to obtain the double-mutant PLCγ2cKO/β-cat.CA animals. Because the double
mice with 10^5 LLC and sacrificed the animals 5 d after tumor challenge when no detectable differences in tumor weight were yet observed (Fig. 7 D). Similar to the global PLCα2-deficient mice, we observed greater accumulation of PLCα2cKO MDSCs compared with CTR in mice with similar tumor size (Fig. 7 D). In contrast, PLCα2cKO/β-cat.CA mice showed significantly lower MDSC expansion than PLCα2cKO mice (Fig. 7 D). Consistent with this observation, the percentage of CD8+ T cells infiltrating the tumor was significantly increased in PLCα2cKO/β-cat.CA compared with PLCα2cKO (Fig. 7 E). As these findings suggested that stabilization of β-catenin levels in PLCα2cKO MDSCs impairs cell immune suppressive activity, we performed functional T cell proliferation assays. CTR-, PLCα2cKO-, and PLCα2cKO/β-cat.CA-MDSCs were cultured with CFSE-labeled WT splenocytes stimulated with anti-CD3 antibody (10 µg/ml). After 3 d, the proliferation of targeted CD8+ T cells was analyzed in terms of CFSE dilution by flow cytometry. As expected from our previous result (Fig. 5 B), CD8+ T cell proliferation is strongly diminished by PLCα2cKO MDSCs compared with control. In contrast, PLCα2cKO/β-cat.CA MDSCs have significantly

mutant mice were born at less than Mendelian rates, rendering the analysis of their tumor phenotype very difficult, we generated radiation chimeras consisting of lethally irradiated WT recipient mice transplanted with bone marrow cells from double-mutant PLCγ2cKO/β-cat.CA animals, PLCγ2cKO or LysM-Cre control mice. 4 wk after bone marrow transplantation, LLC cells were s.c. inoculated into the transplanted mice. Tumor growth was followed for 14 d and the percentage of MDSCs was evaluated by flow cytometry as a marker of immune suppression. Expression levels of PLCγ2 and β-catenin in MDSCs in all chimeric mice were determined by Western blot (Fig. 7 C). Similar to the global PLCγ2−/− mice, PLCγ2cKO chimeric mice also displayed increased tumor growth and MDSC accumulation compared with LysM-Cre chimeric controls (Fig. 7 D). In contrast, chimeric mice bearing double-mutant PLCγ2cKO/β-cat.CA bone marrow cells showed significantly lower tumor growth and MDSC expansion than chimeric mice transplanted with PLCγ2cKO cells (Fig. 7 C). To finally determine whether reduced percentage of PLCγ2cKO/β-cat.CA MDSCs was a consequence of decreased tumor growth, we injected CTR, PLCγ2cKO, and PLCγ2cKO/β-cat.CA mice with 10^6 LLC and sacrificed the animals 5 d after tumor challenge when no detectable differences in tumor weight were yet observed (Fig. 7 D). Similar to the global PLCγ2−/− mice, we observed greater accumulation of PLCγ2cKO MDSCs compared with CTR, in mice with similar tumor size (Fig. 7 D). In contrast, PLCγ2cKO/β-cat.CA mice showed significantly lower MDSC expansion than PLCγ2cKO mice (Fig. 7 D). Consistent with this observation, the percentage of CD8+ T cells infiltrating the tumor was significantly increased in PLCγ2cKO/β-cat.CA compared with PLCγ2cKO (Fig. 7 E). As these findings suggested that stabilization of β-catenin levels in PLCγ2cKO MDSCs impairs cell immune suppressive activity, we performed functional T cell proliferation assays. CTR-, PLCγ2cKO-, and PLCγ2cKO/β-cat.CA-MDSCs were cultured with CFSE-labeled WT splenocytes stimulated with anti-CD3 antibody (10 µg/ml). After 3 d, the proliferation of targeted CD8+ T cells was analyzed in terms of CFSE dilution by flow cytometry. As expected from our previous result (Fig. 5 B), CD8+ T cell proliferation is strongly diminished by PLCγ2cKO MDSCs compared with control. In contrast, PLCγ2cKO/β-cat.CA MDSCs have significantly
Figure 7. Increased β-catenin expression inhibits MDSC expansion, activity, and tumor growth. (A) 10^5 LLC cells were s.c. injected in β-catenin (β-cat.CA) or control mice (CTR), and tumor growth was followed for 14 d. Bone marrow, spleen, and tumors were then analyzed by FACS using anti–Gr-1 and CD11b staining to measure the percentage of MDSCs. Mean ± SD (n = 4) are shown. One representative out of two independent experiments is shown. *, P < 0.05; **, P < 0.01. (B) T cell proliferation assay. MDSCs were isolated from CTR and β-catenin (β-cat.CA) mice, co-cultured with CFSE-labeled splenocytes from WT mice (1:5 and 1:1 ratios) and stimulated with anti-CD3 (10 µg/ml) for 3 d. Bar graphs show mean ± SD of three independent experiments. *, P < 0.05. Representative flow cytometric analysis of gated CD8+ T cell proliferation in the presence of CTR- (dashed line) and β-catenin (β-cat.CA)-MDSCs (solid line) is also provided.
less ability to suppress T cell proliferation compared with PLCγ2 Δ/Δ MDSCs (Fig. 7 F). All together these findings reveal that stabilization of β-catenin in PLCγ2 Δ/Δ MDSCs modulates MDSC expansion and their suppressive activity.

**Reduced PLCγ2/β-catenin in MDSCs occurs during tumor progression in mice and cancer patients**

We then wondered if down-regulation of PLCγ2/β-catenin pathway is an important regulatory mechanism involved in the aberrant MDSC expansion and/or activity during tumor progression. To test the hypothesis that down-regulation of PLCγ2/β-catenin pathway occurs in WT MDSCs, we compared protein expression levels of phosphorylated-PLCγ2 (p-PLCγ2) and β-catenin in MDSCs isolated from tumor-free and tumor-bearing WT mice. Strikingly, we found down-regulation of p-PLCγ2 and β-catenin levels in MDSCs isolated from WT tumor-bearing mice compared with tumor-free controls. Both LLC and B16 tumor cell lines induced a similar phenomenon (Fig. 8 A).

Because various studies implicated MDSCs in the metastatic process (Li et al., 2013; Sawant et al., 2013; Yu et al., 2013), we wondered whether down-regulation of PLCγ2/β-catenin signaling in MDSCs would also occur at late stages of tumor dissemination. To answer this question, we injected firefly-conjugated B16 melanoma (B16-Fl) cells into the left ventricle of WT animals, a model widely used to study tumor dissemination to bone, visceral organs, and lungs in C57BL/6 mice (Arguello et al., 1988; Kang et al., 2003). Animals receiving saline were used as negative control. Recruitment of tumor cells to bone was assessed by bioluminescence imaging. Mice were sacrificed on day 14 when tumor cells were readily detectable in bones, and increased percentage of MDSCs in the bone marrow and the spleen compared with tumor-free controls was confirmed by FACS. Importantly, we also observed reduced p-PLCγ2 and β-catenin protein levels in MDSCs isolated from spleens of animals bearing bone metastases compared with controls (Fig. 8 B). Thus, the down-regulation of PLCγ2/β-catenin axis in MDSCs occurs in mice with primary s.c. tumors as well as during tumor dissemination.

As increased percentage of MDSCs in peripheral blood correlates with disease progression and stage in many human cancers, including pancreatic cancer (Porembka et al., 2012), we isolated MDSCs from PBMCs of pancreatic cancer patients and healthy donors to compare p-PLCγ2 and β-catenin expression levels. Similarly to mice, we isolated the whole human MDSC population, characterized by the co-expression of CD11b and the common myeloid marker CD33 (Greten et al., 2011; Filipazzi et al., 2012). All samples were collected before surgical or medical therapy. 5 patients (49–74 yr of age), 2 with resectable T2A or T3 stages and 3 with unresectable T3 or T4 stages of pancreatic ductal adenocarcinoma were tested by Western blot. Considering the variability between individuals, we normalized protein levels with total amount of protein loaded visualized by β-actin. We found significant reduction of p-PLCγ2 and its downstream effector p-PKC in MDSCs from pancreatic cancer patients compared with healthy donors. β-catenin and p-GSK3β levels were also decreased (Fig. 8 C). In conclusion these results demonstrate that the down-regulation of PLCγ2/β-catenin signaling is a critical step in MDSC expansion in humans and mice.

**DISCUSSION**

The mechanism behind MDSC differentiation and the signals that control their commitment and biological function in tumor-bearing hosts are not well understood. MDSCs have been detected in bone marrow, secondary lymphoid organs, and tumor site in many murine tumor models and in patients with advanced malignancies (Young et al., 1988; Gabitass et al., 2011; Porembka et al., 2012). The variability in the percentage of MDSCs and their efficiency to suppress antitumor T cell responses depend on the type and stage of tumor (Youn et al., 2008; Dolcetti et al., 2010; Younos et al., 2011). Several studies focused on identifying tumor-derived factors involved in the accumulation of MDSCs (Bronte et al., 2000; Barreda et al., 2004; Serafini et al., 2006; Pan et al., 2008; Roland et al., 2009; Xiang et al., 2009). Fewer studies, however, analyzed the signaling pathways involved in MDSC expansion in the tumor host. We now provide new evidence demonstrating that down-regulation of PLCγ2 and β-catenin signaling promotes MDSC accumulation in the bone marrow and subsequent recruitment to secondary lymphoid organs and tumor site, where they favor tumor escape from immune control. We found that PLCγ2 Δ/Δ MDSCs, with reduced β-catenin levels, are increased in number and strongly suppress CD8+ T cell activity via production of ROS and NO species. This increase in MDSC number and immune suppressive effects is likely responsible for the greater s.c. growth of LLC and B16 tumor cell lines and for the allogeneic tumor progression shown. (C) WT mice were lethally irradiated and transplanted with bone marrow cells from PLCγ2Δ/Δ, LysM-Cre (CTR), or PLCγ2Δ/Δ/β-catenin CA to generate chimeric mice. Western blot analyses show the expression of PLCγ2, β-catenin, p-PKC, p-GSK3β, and β-actin in MDSCs from chimeric mice. 4 wk after BM transplantation, chimeric mice were inoculated s.c. with 10^5 LLC cells and tumor growth was followed for 14 d. Percentage of MDSCs in bone marrow, spleen, and tumor was analyzed by FACS at time of sacrifice. Mean ± SD (n = 10) are shown. Data are reported from one of two similar independent experiments. **P < 0.01; ***P < 0.001. (D and E) 10^5 LLC cells were s.c. injected in PLCγ2Δ/Δ, CTR, or PLCγ2Δ/Δ/β-catenin CA mice. 5 d after tumor challenge, the tumor was resected and weighed (D). Percentage of MDSCs from bone marrow, spleen, and tumor were then analyzed by FACS staining (Gr-1+CD11b+, MDSCs) (D). Dissected tumors were stained with anti-Cd8 antibody and the percentage of CD8+ T cells was determined by FACS (E). Results represent mean ± SD (n = 3). One representative out of two independent experiments is shown (D and E). *, P < 0.05; **, P < 0.01. (F) T cell proliferation assay. 5 d after LLC tumor inoculation, MDSCs were isolated from CTR, PLCγ2Δ/Δ, and PLCγ2Δ/Δ/β-catenin CA mice, co-cultured for 3 d with CFSE-labeled splenocytes from WT mice (1:5 and 1:1 ratios), and stimulated with anti-CD3 (10 μg/ml). Bar graphs show mean ± SD of three independent experiments. *, P < 0.05.
of 4T1 breast carcinoma cells observed in PLCγ2−/− mice. Although a tumor/MDSCs vicious cycle is expected to take place, in which larger tumors cause greater MDSC expansion to promote tumor escape from immune control, we found increased PLCγ2−/− MDSCs numbers at early time points after tumor inoculation, when differences in tumor size between WT and KO mice were not present. Although DC and NK cells from PLCγ2−/− mice also have functional defects and could enhance tumor growth in PLCγ2−/− mice, the MDSCs adoptive transfer studies demonstrate that PLCγ2−/− MDSCs alone can greatly increase tumor progression in WT recipient mice. This finding indicates that PLCγ2 controls MDSC development and/or proliferation in response to the tumor.

Enhanced accumulation of MDSCs is also likely to be responsible for the unexpected bone tumor phenotype recently observed in PLCγ2−/− animals (Zhang et al., 2011). In the bone metastasis field, it has been established that bone resorbing osteoclasts are required to sustain tumor growth in bone. Interestingly, PLCγ2−/− mice display enhanced tumor growth in bone despite decreased osteoclast numbers, due to impaired CD8+ T cell activation (Zhang et al., 2011). Thus, expansion of PLCγ2−/− MDSCs in this tumor model seems to overcome the requirement for active osteoclasts to sustain tumor growth in bone. Importantly, the down-regulation of PLCγ2 and β-catenin can also occur in MDSCs from WT mice during tumor dissemination to bone, indicating that PLCγ2/β-catenin pathway modulates MDSC expansion in primary tumors as well as in a metastatic setting.

Similarly to PLCγ2−/− mice, mice with deletion of β-catenin in the myeloid compartment are more susceptible to tumor growth due to increased MDSC numbers, whereas expression of a constitutively active form of β-catenin decreases MDSC accumulation and tumor growth. Importantly, expression of β-catenin constitutively active in PLCγ2−/− deficient MDSCs is also sufficient to reduce the expansion and the immune...
suppressive activity of PLCγ2−/− MDSCs, allowing greater infiltration of CD8+ T cells at tumor site. Consequently, tumor growth is reduced in PLCγ2cKO/β-cat.CA mice compared with PLCγ2cKO animals. The importance of down-regulation of PLCγ2–β-catenin axis in MDSC accumulation and activity is not limited to our KO mouse models but it is a general mechanism involved in the modulation of WT MDSC responses occurring in the presence of tumor, including in cancer patients. Our data show that pancreatic cancer patients at advanced stage have reduced p-PLCγ2 and β-catenin levels compared with MDSCs isolated from healthy controls. These results demonstrate that PLCγ2 is a negative regulator of MDSC expansion and immune suppressive effects in tumor-bearing hosts via the β-catenin pathway in humans and mice. Several questions arise from this finding.

How is PLCγ2 signaling regulated in MDSCs? Activation of PLCγ2, via phosphorylation of its tyrosine residues, is often observed in hematopoietic cells, including myeloid cells, as well as in cancer cells downstream of ITAM-containing immune receptors, growth factor receptors, and G protein-coupled receptors. Considering that the tumor microenvironment is enriched with tumor-derived factors that can potentially signal via PLCγ2, it was very surprising to observe reduction of PLCγ2 phosphorylation in MDSCs from tumor-bearing mice and cancer patients compared with healthy controls. In myeloid cells PLCγ2 activation downstream of ITAM containing receptors can be counterbalanced by negative regulatory signals emanated by receptors containing ITIM domains. A recent study indicated that the ITIM-containing paired immunoglobulin-like receptor (PIR) B is highly expressed in MDSCs (Ma et al., 2011). Deletion of PIR-B switches the MDSC phenotype from immune-suppressive to proinflammatory, thus leading to reduced tumor growth. Therefore, one possible mechanism for down modulation of PLCγ2 activation in WT MDSCs would be through suppression of ITAM signaling by PIR-B. Because β-catenin activation has also been reported to occur downstream of ITAM receptors (Otero et al., 2009), reduced β-catenin levels in MDSCs isolated from tumor-bearing mice or cancer patients could also be caused by suppression of ITAM signaling by PIR-B.

How does PLCγ2 modulate β-catenin? Regardless of which ITAM-containing receptor may activate PLCγ2 and β-catenin, we propose that these molecules lie on the same pathway. This assumption is supported by the observation that β-catenin levels are reduced in PLCγ2−/− MDSCs and that expression of constitutively active β-catenin in PLCγ2−/− marrow cells limits MDSC expansion and immune suppressive effects and reduces tumor growth. Although PLCγ2 has never been shown to directly modulate β-catenin levels, activation of PKC can induce β-catenin stabilization in T cells (Lovatt and Bijlmakers, 2010). It is likely that PKC, a downstream effector of PLCγ2, phosphorylates and thus inactivates GSK3β, a kinase that targets β-catenin for ubiquitination and subsequent proteasomal degradation. In support of this hypothesis, we observed impaired PKC phosphorylation and reduced p-GSK3β levels in PLCγ2−/− MDSCs compared with WT, whereas the rescue of PKC activation by PDBu in PLCγ2−/− MDSCs increases β-catenin protein levels. Nevertheless, we cannot exclude additional PLCγ2-independent down-regulation of β-catenin in MDSCs, possibly via modulation of Wnt ligands or Wnt inhibitors by the tumor cells.

How does β-catenin control MDSC expansion? Elevated levels of β-catenin are often associated with increased cell proliferation. This is especially true for cancer cells. Therefore, it was puzzling to observe that MDSC expansion was associated with reduced β-catenin levels. β-catenin has been extensively analyzed in hematopoiesis; at times leading to contradictory findings. Conditional expression of a stabilized, active form of β-catenin in hematopoietic stem cells (HSC) resulted in hematopoietic failure because of a reduction in cell cycle quiescence, HSC exhaustion, and blocked differentiation. Consistent with our hypothesis that β-catenin limits MDSC expansion, constitutive activation of β-catenin in early hematopoietic precursors significantly reduces the Gr-1+CD11b+ myeloid cell population (Scheller et al., 2006). Thus, it is possible that down-regulation of β-catenin, rather than controlling MDSC proliferation, allows MDSC accumulation by preventing their differentiation into mature myeloid cells. In support of this hypothesis, we find that in vitro cultures of hematopoietic progenitor cells from PLCγ2-deficient mice give rise to less mature myeloid populations but more Gr-1+ cells than WT cultures. Another plausible mechanism that could lead to accumulation of MDSCs in tumor-bearing PLCγ2- and β-catenin–null animals would be through increased differentiation from myeloid progenitors in the bone marrow. Several transcription factors involved in myelopoiesis such as interferon–regulatory factor 8 (IRF-8), C/EBP-β, and PU.1 have been demonstrated to regulate MDSC development (Scheller et al., 1999; Schroeder et al., 2003; Kistetter et al., 2006; Marigo et al., 2010). However IRF-8, PU.1, and C/EBP-β are also involved in monocyte/macrophage maturation, neutrophil differentiation, and/or DC development (Tamura et al., 2000; Hamdorf et al., 2011; Batliner et al., 2012; Pham et al., 2012). Therefore, further studies are required to determine whether down-regulation of PLCγ2–β-catenin pathway may affect MDSC differentiation via transcriptional regulation.

In conclusion, our results identify the PLCγ2–β-catenin pathway as a negative modulator of MDSC accumulation and activation in response to tumors. This finding is clinically relevant because we confirmed down-regulation of PLCγ2 and β-catenin in human MDSCs isolated from pancreatic cancer patients. This observation is particularly important, as β-catenin targeting is currently in clinical trials because of the positive role of β-catenin on cell growth in many cancers. However, based on our finding this approach could be undermined by tumor escape from immune control through expansion of MDSCs.

MATERIALS AND METHODS

Animals and tumor models. Animals were housed in a pathogen-free animal facility at Washington University. 6–8-wk-old littermate mice were used in all experiments according to protocols approved by the Institutional Animal Care and Use Committee.
Animal Care and Use Committee. PLCy2−/− mice were on a C57BL/6 background and have been previously described (Wang et al., 2000). WT and PLCy2−/− littermates were used throughout the study. LysM-Cre/β-cateninlox/lox (conditional KO, β-cat.KO) and LysM-Cre/β-cateninfloXfloX/ floXfloX (constitutively active, β-cat.CA) mice on C57BL/6 background were provided by F. Long (Washington University, St. Louis, MO) and have been previously described (Clausen et al., 1999; Harada et al., 1999; Brault et al., 2001). In brief, β-cateninlox/lox mice bear two LoxP sites flanking exons 2–6, which lead to a loss-of-function deletion upon Cre-mediated excision. In β-cateninfloXfloX/floXfloX mice, excision of exon 3 leads to a stabilized, non-degradable form of β-catenin. C57BL/6 PLCy2−/− mice were obtained from T. Kurosaki (Kansai Medical University, Moriguchi, Japan; Hashimoto et al., 2000, and the mating strategy to obtain the conditional KO under the LysM-Cre promoter (PLCy2-KO) was performed in our laboratory. LysM-Cre and floxed littersates were used as controls (CTR). All in vivo figures are shown as representative experiments. Importantly, significant differences are shown when all CTR groups are pooled together (Fig. 6 C and Fig. 7 A).

CD45.1 C57BL/6 WT mice used for the MDSC transfer experiments were purchased from The Jackson Laboratory. C57BL/6 OT-1 mice were obtained from M. Colonna’s laboratory (Washington University, St. Louis, MO). B16 (C57BL/6 murine melanoma cells), LLC (C57BL/6 murine LLC cells), and 4T1 (BALB/c murine mammary tumor cells) were cultured at 37°C in complete media (DMEM supplemented with 2 mM t-glutamine, 100 µg/ml streptomycin, 100 IU/ml penicillin, and 1 mM sodium pyruvate) containing 10% FBS. To establish tumors, B16 (106), LLC (106) or BALB/c 4T1 (5 × 106) tumor cells were suspended in PBS and inoculated s.c. in the flank of mice. Tumor measurements were performed every 2 or 3 d with a caliper, and volumes were calculated using the following formula: V = ½ length (mm) × width (mm)².

For adoptive transfer experiments, appropriate control mice and indi-
cated KO (PLCy2−/− or β-cat.cKO) animals were s.c. injected with 105 LLC. 14 d after tumor xenograft, MDSCs were isolated from the spleen as described below, and 3 × 10⁶ MDSCs were i.v. injected into WT tumor-bearing mice on days 3 and 6 after tumor challenge. WT mice receiving saline injection on days 3 or 6 were used as additional controls.

104 firefly-conjugated B16 melanoma cells (B16-F1) suspended in 50 µl of saline solution were injected into the left cardiac ventricle (i.v.) of 6–8 wk-old female mice as previously described (Arguello et al., 1988; Kang et al., 2003). Recruitment of tumor cells to bone was monitored on days 9, 12, and 14 by bioluminescence imaging using an IVIS 100 imaging system (Caliper Life Sciences). Mice with extrapleural intrathoracic tumors were excluded from analysis. Bioluminescence photon flux (photons per second) data were measured by bioluminescence imaging using an IVIS 100 imaging system (Caliper, MA). Mice with extrapleural intrathoracic tumors were excluded from analysis. Bioluminescence photon flux (photons per second) data were measured by bioluminescence imaging using an IVIS 100 imaging system (Caliper, MA).

Bone marrow transplantation. 4-wk-old female C57BL/6 mice were lethally irradiated using a 137Cs source with 1,000 rads to generate recipient mice. Bone marrow was harvested from 6–8 wk-old female PLCy2-KO, PLCy2-KO/β-cat.CA, or LysM-Cre control mice. Cells were then suspended in PBS and 10⁶ cells/200 µl were injected into the lateral tail vein of recipient mice. 4 wk after bone marrow transplantation, these mice were inoculated with tumor cells as described above.

Flow cytometric analysis. Immediately upon sacrifice, single-cell suspensions were prepared from bone marrow, spleen, and tumor. In brief, bone marrow cells were harvested from tibia and femurs by centrifugation, whereas spleens and tumors were mechanically dissociated and individual cell suspensions obtained through 70-µm cell strainer. Red blood cells were then removed with lysis buffer and cells counted. Cell suspensions were then washed and stained in PBS with 0.5% FBS with the following anti–mouse antibodies: allophycocyanin (APC)-conjugated anti–Gr-1 or -Ly6G, FITC-conjugated anti-F4/80 (BioeScience); and phycoerythrin (PE)-conjugated antibodies to CD11b or CD11c, FITC-conjugated anti-Ly6G, -CD11c, -CD86 (B7.2), or -CD45.1, APC-conjugated anti-CD8α (BD). The respective isotype-matched conjugated controls were purchased from eBioscience and BD respectively. Cell surface staining on isolated cells from human PBMCs were performed using monoclonal (PerCP-Cy5.5)-conjugated anti–human CD33 antibody (BioLegend) and (PE)-conjugated anti–human CD11b antibody (BD). Corresponding isotope controls yielded no significant staining. Acquisition was performed on a FACSCalibur and the dedicated software CellQuest (BD). Data were analyzed with FlowJo 7.5.5 software (Tree Star).

MDSC isolation. In vivo experiments were assessed using freshly isolated MDSCs from spleens of tumor-bearing mice. Cells were purified by immuno-
magnetic separation using biotinylated anti–Gr-1 antibody and streptavin-
din-conjugated MicroBeads with MiniMACS columns according to the manufacturer’s protocol (Miltenyi Biotec). In vitro functional and mechanistic as-
tays were done either with whole MDSC population or with PMN- and MO-MDSC subsets. Cells were isolated from spleens of tumor-bearing mice using the Myeloid-Derived Suppressor Cell Isolation kit from Miltenyi Biotec. Cell purity was checked by flow cytometric analysis using anti–CD11b and Gr-1 antibodies (>95%), and viability was checked by Trypan blue dye exclusion.

Human PBMCs were obtained from D.C. Linehan’s laboratory (Wash-
ington University, St. Louis, MO) as previously described (Porembka et al., 2012). In brief, informed consent was prospectively obtained from all patients before obtaining human blood according to the institutionally approved Human Studies Committee Protocol. Peripheral blood samples were collected in vacuum tubes containing EDTA (BD). PBMCs were iso-
lated by Ficol/density centrifugation and frozen in DMSO with 10% FBS. Cells were then thawed, washed, and processed for cell isolation using CD33 and CD11b MicroBeads with MiniMACS columns according to the manu-
facturer’s protocol (Miltenyi Biotec). Purity was confirmed by flow cytometric (>95%) and Western blot analyses, which were immediately performed.

Real-time PCR. MDSCs from spleens were isolated 14 d after tumor challenge as previously described. Total RNA was extracted with TRIzol (Invitrogen) and quantified on ND-1000 spectrophotometer (NanoDrop Technologies). The cDNA was synthesized with 1 µg RNA using RNA to DNA EcoDry Premix (oligo d T)-RT-PCR kit from Takara. The amount of Bcl-2, Bcl-xl, or Bax was determined using Power SYBR Green mix on 7300 Real-Time PCR System (Applied Biosystems). Cyclophilin mRNA was used as internal control. Specific primers were as follows: Bcl-2, 5'-TGATGACTGGCTGACCAAGC-3' and 5'-CATCCACCAGCTCTGTTAT-3'; Bcl-xl, 5'-ACAGAGACGACCCAGTAATG-3' and 5'-ACCGAGTAAAACACTT-3'; Bax, 5'-ACAGATCAGGAAAGGGG-3' and 5'-CAATTAGGAAGGGCAACC-3'; cyclin D1, 5'-AGCCATAACGTTCCTTCCGAT-3' and 5'-TTACCTCCAAAAGACACAC-3'. Relative quantification of transcription was calculated as the power of the difference between amplification of the target gene and amplification of cyclophilin (i.e., 2−[(ΔΔCt)target−ΔΔCtcontrol]).

Generation of cells from bone marrow progenitors. Hematopoietic progenitor cells (HPCs) were isolated from WT and PLCy2−/− bone mar-
row using the Lineage Cell Depletion kit (Miltenyi Biotec). 5 × 10⁶ HPCs were cultured in 24-well plates containing 2 ml of RPMI 1640 supplemented with 10% FBS, 20 ng/ml GM-CSF, 10 ng/ml IL-4, and 20% vol/vol tumor conditioned medium (TCM; Youn et al., 2008). The TCM was generated from primary EL-4 tumor cells injected into WT C57BL/6 for 2 wk, collected as single-cell suspension with collagenase and cultured for 2 d in RPMI supplemented with 10% FBS. TCM were frozen at −80°C until further use. After 5 d of HPC cultures, percentages of CD11c+CD11b+ and CD11b+ F4/80+ and Gr-1+ cells in total WT and PLCy2−/− cell cultures were analyzed by flow cytometry.

T cell suppression assay. Freshly isolated splenocytes (5 × 10⁶ cells/ml) from OT-1 TCR transgenic mice were depleted of red cells and labeled with CFSE (1 µM; Molecular Probe, Carlsbad, CA) for 10 min at 37°C and washed with fresh culture media, according to the manufacturer’s instructions. OT-1
Bone marrow cell suspensions were harvested as previously described and plated in 6-well plates (3 × 10^6 cells/ml) with RPMI supplemented with 10% FBS and 10 ng/ml GM-CSF. MDSCs were isolated as previously described and prepared for Western blot analyses as described below.

Western blotting. MDSCs were isolated as previously described and immediately lysed with RIPA buffer in the presence of protease and phosphatase inhibitors. An equal amount of total protein lysates were subjected to 8% SDS-PAGE gel and transferred to PVDF membranes. Membranes were blocked in 5% BSA in PBS/Tween-20 for 1 h, and then probed with appropriate specific primary antibodies overnight at 4°C. Membranes were washed and incubated for 2 h at room temperature with secondary antibody-conjugated with peroxidase. Results were visualized by chemiluminescence detection using a SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific). Antibodies against p-PLCγ2 (Y213), total β-catenin, p-PKC (pan; BH Ser660), and p-GSK3β (Ser9) were obtained from Cell Signaling Technology. Equal loading was assessed using anti-β-actin antibody (Sigma-Aldrich). Semi-quantifications of protein were determined using GeneTools software (Syngene).

Statistical analysis. Experiments were done in triplicate and analyzed using Student’s t-test. In calculating two-tailed significance levels for equality of means, equal variances were assumed for the two populations. Results were considered significant at P < 0.05.

We gratefully thank Tonia Thompson for research administration and Train Lupu for his help for the in vivo experiments (Department of Orthopaedics, Washington University). We thank Drs. Marina Cella and Marco Colonna for their gift of OT-1 mice. We thank the Washington University Bright Institute and Molecular Imaging Center (P50 CA94056ADD). This work was supported by a National Institutes of Health (NIH) grant to R. Faccio (RO1 AR52921), Shriners Hospital Fund to R. Faccio, Bright Institute Pilot Research grant to R. Faccio, NIH grant to D.V. Novack (AR052705 and EB007568), and the Barnes-Jewish Foundation (D.V. Novack). This work was also supported by Barnes Jewish Hospital Cancer Frontier Fund (D.C. Linehan). The authors declare no conflict of interest.

REFERENCES


